FORM-2 THE PATENT ACT 1970 (39 of 1970) & The Patents Rules, 2003 COMPLETE SPECIFICATION (Section 10 and Rule 13) 1. TITLE OF THE INVENTION: - A Process For The Synthesis Of N-(aryl)-3-Oxo-3- Phenylpropanamide Derivatives And Their Antileukemic Activity. 2. ADDRESS OF THE APPLICANT (S):- 1) Dr. M. M. V. Ramana 2) Dr. R. S. Lokhande 3) Ankita L. Mehta NATIONALITY: INDIAN NATIONALITY: INDIAN NATIONALITY: INDIAN Department of Chemistry. Department of Chemistry, Department of Chemistry University of Mumbai, Jaipur National University, Jaipur National University, Vidyanagari, Jagatpura, Jagatpura, Santacruz (East), Jaipur- 302017. Jaipur- 302017. Mumbai- 400098. 3. PREAMBLE TO THE DESCRIPTION: - COMPLETE The following specification particularly describes the invention and the manner in which it is to be performed. 4. DESCRIPTION:- Title: - A process for the Synthesis of N-(aryl)-3-oxo-3-phenylpropanamide derivatives and their antileukemic activity. Abstract of the invention:- The present invention relates to the synthesis of small molecules showing cytostatic/cytotoxic potential against leukemia. Study relates to a process for the preparation of N-(aryl)-3-oxo-3-phenylpropanamide derivatives and their anti leukemic activity. Background of invention and Prior art:- Leukemia is cancer of the body's blood-forming tissues, including the bone marrow and the lymphatic system. Leukaemia originates in developing blood cells, which have undergone a malignant change. They multiply in an uncontrolled way and do not mature as they are supposed to. Because they have not matured properly, these cells are unable to function properly. Most cases of leukaemia originate in developing white cells. In a small number of cases leukaemia develops in other blood-forming cells, for example in developing red cells or developing platelets. The four major types of leukemia are acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia and chronic lymphocytic leukemia. Cancerous change takes place in a type of marrow cell that forms lymphocytes, the leukemia is called "lymphocytic" (or "lymphoblastic"). If the cell change takes place in a type of marrow cell that normally goes on to form red blood cells, some kinds of white blood cells and platelets, the leukemia is called "myeloid." Acute leukemia is a rapidly progressing disease that affects mostly cells that are partly or completely undeveloped. These immature cells cannot perform their normal functions. Chronic leukemia typically progresses slowly, and permits the growth of greater numbers of more developed cells. In general, these more mature cells can carry out some of their normal functions. Both diseases are characterized by poor response to standard therapies. Consequently there is growing interest in the search for novel anticancer substances with high efficacy, low toxicity, and minimal side effects. Research on antileukemic activity are well known in the prior arts including U.S. Pat. No. US 2009/146546A1; U.S. Pat. No. US 2004/024160 Al. New anti-cancer agents with unique mechanisms of action have been developed, many of them exhibit low tumor selectivity. Recent drug discovery efforts are highly focused on the design and the synthesis of small molecules as anticancer agents. There are several reports (US 6,166,016 ) on biological activity of amide derivatives, including pharmacological roles, prevention and treatment of tissue damage, also useful as analgesics, anti¬inflammatory agents, antimicrobial drugs, hypoglycemic agents, hypolipidemic agents, antihypertensive agents and anti-cancer agents. The present invention describes the synthesis of N-(aryl)-3-oxo-3-phenylpropanamide derivatives 3a -31 (Scheme) and their cytotoxicity evaluation (Table) against leukemia cell line K562. Description of the invention:- The main objective of the present invention is to synthesize small-molecule inhibitors of tyrosine kinase enzyme showing potential against leukemia. The present invention is successful in attaining all the above objectives. According to the invention there is provided a process for the preparation of N-(aryl)-3-oxo-3-phenylpropanamide derivatives (Scheme). Table shows the results of antileukemic testing of the synthesized compounds against K-562 cell line. These results are expressed in terms of percent growth in the presence of the test compounds. The GI50 values are shown in Table. Scheme Table Tumor cell cytotoxicity of compounds 3a-31 on human cancer cell line K-562 Sr.No Compounds GI50 (μM) 1 3a <0.1 2 3b 33.2 3 3c <0.1 4 3d 10.7 5 3e 60.7 6 3f 9.4 7 3g >100 8 3h 48.0 9 3i >100 10 3j >100 11 3k <0.1 12 31 <0.1 13 Imatinib Mesylate 0.26 In conclusion, compounds 3a, 3c, 3d, 3f, 3k, and 31 show promising antileukemic activity against K562 cell line. Exarriples:- Compounds la-11 and 2 are commercially available. Example-1 Preparation ofN-(2-methoxy-5-nitrophenyl)-3-oxo-3-phenylpropanamide(3a). A mixture of 2-methoxy-5-nitrobenzamine (la) (1.512 gm, 0.009 mol) and benzoylacetic ethyl ester (2) (1.728gm, 0.009 mol) were taken in a round bottom flask and heated at 150 °C in a heating mantle for 4 hours. The reaction mixture was then allowed to cool and the solid was recrystallized from dichloromethane to afford light yellow crystals of N-(2-methoxy-5-nitrophenyl)-3-oxo-3-phenylpropanamide (3a) (81 % Yield), m.p.: 183-185 °C (O. Turan, Mc. Alexander; Canadian Journal of chemistry, 2000, 78(9), 1158-1164. The spectral data (Mass, ]1H NMR) was also consistent with the reported data (O. Turan, Mc. Alexander; Canadian Journal of chemistty, 2000, 78(9), 1158-1164). Example-2 Preparation of N-(3-(trifluoromethyl) phenyl)-3-oxo-3-phenylpropanamide (3b). It was prepared as described in Example-1 by using 3-trifluoromethyl aniline (lb) (1.12 gm, 0.009 mol) in place of 2-methoxy-5-nitrobenzamme (la). The crude solid was recrystallized from dichloromethane to afford white crystals of N-(3-(trifluoromethyl) phenyl)-3-oxo-3-phenylpropanamide (3b) (84 % Yield). m.p.: 131-133 °C IR (cm-1): 3287, 2967, 1681, 1665, 1597, 1331 1H NMR (300 MHz, CDCI3) 5: 9.62 (br s, 1H), 8.19 (s, 1H), 7.88 (m, 5 H), 7.56 (m, 3 H), 4.21 (s, 2 H); 13C NMR (75 MHz, CDC13) δ keto form (major): 194.82, 166.59, 140.75, 140.45, 137.48, 134.37, 131.68, 130.70, 129.50, 126.97, 123.87, 123.46, 120.77,48.70; HRMS: m/z cal. mass forC16H|13F3NO2 [M+H]+= 308.07, obs. mass [M+H]+= 308.15. Example-3 Preparation of N-(4-(trifluoromethyl) phenyl)-3-oxo-3-phenylpropanamide (3c) It was prepared as described in Example-1 by using 4-(trifluoromethyl) aniline